VANCOUVER, Jan. 17 /CNW/ - Protox(TM) Therapeutics Inc. (TSX-V: PRX) will
hold a conference call to discuss interim clinical results for its ongoing
Phase I prostate cancer study for PRX302. Dr. Fahar Merchant, President and
Chief Executive Officer will host the call. A press release outlining the
interim results will be disseminated tomorrow morning before market hours.
